Abstract
Interferons (IFNs) are a subclass of lymphocyte-released cytokines that interfere with intracellular viral replication. These drugs are classified into three groups: IFN type 1 (IFN-α, IFN-β, and IFN-ω), IFN type 2 (IFN-γ), and IFN type 3 (IFN-λ). Despite numerous trials, IFN therapy has yet to conclusively demonstrate superiority in the treatment of various pulmonary diseases. In addition to the FDA-approved and ongoing investigational uses for IFN therapy, there is a debate regarding the appropriate dosage of these agents. A retrospective literature review is moving experts towards low-dose therapies in nearly every application of IFN therapy. It is speculated that known and unknown toxicity may limit the beneficial effects of IFN therapy.
Keywords: Asthma, idiopathic pulmonary fibrosis, influenza, interferon.
Current Respiratory Medicine Reviews
Title:The Use of Interferons in Respiratory Diseases
Volume: 9 Issue: 5
Author(s): Ori-Michael J. Benhamou, Miriam Jacobs, Jonathan Drew, Shahar Geva, Maor Waldman and Or Kalchiem-Dekel
Affiliation:
Keywords: Asthma, idiopathic pulmonary fibrosis, influenza, interferon.
Abstract: Interferons (IFNs) are a subclass of lymphocyte-released cytokines that interfere with intracellular viral replication. These drugs are classified into three groups: IFN type 1 (IFN-α, IFN-β, and IFN-ω), IFN type 2 (IFN-γ), and IFN type 3 (IFN-λ). Despite numerous trials, IFN therapy has yet to conclusively demonstrate superiority in the treatment of various pulmonary diseases. In addition to the FDA-approved and ongoing investigational uses for IFN therapy, there is a debate regarding the appropriate dosage of these agents. A retrospective literature review is moving experts towards low-dose therapies in nearly every application of IFN therapy. It is speculated that known and unknown toxicity may limit the beneficial effects of IFN therapy.
Export Options
About this article
Cite this article as:
Benhamou J. Ori-Michael, Jacobs Miriam, Drew Jonathan, Geva Shahar, Waldman Maor and Kalchiem-Dekel Or, The Use of Interferons in Respiratory Diseases, Current Respiratory Medicine Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/1573398X10666140520004706
DOI https://dx.doi.org/10.2174/1573398X10666140520004706 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
<i>Epimedium brevicornum</i> Maxim and its Efficacy in the Treatment of Sexual Dysfunction
The Natural Products Journal Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Reduction of eNOS in Vascular Smooth Muscle by Salt Independently of Hypertension
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases
Current Drug Targets Omalizumab: Not Only For Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke
Current Drug Targets - CNS & Neurological Disorders Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Current Pharmacogenomics and Personalized Medicine Pathophysiology of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Oxidative Stress: Meeting Multiple Targets in Pathogenesis of Diabetic Nephropathy
Current Drug Targets Action and Disposition of the β3-Agonist Nebivolol in the Presence of Inflammation; An Alternative to Conventional β1-Blockers
Current Pharmaceutical Design Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Practical Approach to Children Presenting with Eosinophila and Hypereosinophilia
Current Pediatric Reviews Insulin-Degrading Enzyme: Structure-Function Relationship and its Possible Roles in Health and Disease
Current Pharmaceutical Design Synthetic Approaches to the Multifunctional Drug Ebselen and Analogs: Past and Present
Mini-Reviews in Organic Chemistry The Interplay between Cofilin and Phospho-Cofilin: Its Role in Maintaining Blood Brain Barrier Integrity
CNS & Neurological Disorders - Drug Targets Mediterranean Diet, Brain and Muscle: Olive Polyphenols and Resveratrol Protection in Neurodegenerative and Neuromuscular Disorders
Current Medicinal Chemistry Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology